Skip to content
OpenCapital
Get started

MoonLake Immunotherapeutics MLTX Consultant and other fees

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.49B-45.9%
Enterprise value$1.29B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept mnlk:AccruedConsultingAndOtherFeesCurrent.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's consultant and other fees.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's consultant and other fees?
MoonLake Immunotherapeutics (MLTX) reported consultant and other fees of $363K in Q1 2026.
How has MoonLake Immunotherapeutics's consultant and other fees changed year-over-year?
MoonLake Immunotherapeutics's consultant and other fees decreased by 56.4% year-over-year, from $833K to $363K.
What is the long-term trend for MoonLake Immunotherapeutics's consultant and other fees?
Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's consultant and other fees has grown at a 71.9% compound annual growth rate (CAGR), from $49.21K to $430K.